FR10C0056I2 - - Google Patents
Info
- Publication number
- FR10C0056I2 FR10C0056I2 FR10C0056C FR10C0056C FR10C0056I2 FR 10C0056 I2 FR10C0056 I2 FR 10C0056I2 FR 10C0056 C FR10C0056 C FR 10C0056C FR 10C0056 C FR10C0056 C FR 10C0056C FR 10C0056 I2 FR10C0056 I2 FR 10C0056I2
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94200521 | 1994-03-02 | ||
EP95912188A EP0746317B1 (en) | 1994-03-02 | 1995-03-01 | Sublingual or buccal pharmaceutical composition |
PCT/EP1995/000765 WO1995023600A1 (en) | 1994-03-02 | 1995-03-01 | Sublingual or buccal pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
FR10C0056I1 FR10C0056I1 (it) | 2011-01-28 |
FR10C0056I2 true FR10C0056I2 (it) | 2011-11-25 |
Family
ID=8216678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR10C0056C Active FR10C0056I2 (it) | 1994-03-02 | 2010-12-23 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5763476A (it) |
EP (1) | EP0746317B1 (it) |
JP (2) | JP4099224B2 (it) |
KR (1) | KR100330942B1 (it) |
CN (1) | CN1079670C (it) |
AT (1) | ATE167057T1 (it) |
AU (1) | AU692530B2 (it) |
BR (2) | BR9506924A (it) |
CA (1) | CA2182981C (it) |
CZ (1) | CZ284633B6 (it) |
DE (2) | DE122010000050I2 (it) |
DK (1) | DK0746317T3 (it) |
ES (1) | ES2118584T3 (it) |
FI (1) | FI117923B (it) |
FR (1) | FR10C0056I2 (it) |
HK (1) | HK1008417A1 (it) |
HU (1) | HU225051B1 (it) |
LU (1) | LU91751I2 (it) |
NO (2) | NO308772B1 (it) |
NZ (1) | NZ282394A (it) |
PL (1) | PL180465B1 (it) |
RU (1) | RU2139051C1 (it) |
WO (1) | WO1995023600A1 (it) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032108A1 (en) * | 1997-12-19 | 1999-07-01 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
ATE516799T1 (de) * | 2002-02-13 | 2011-08-15 | Michael K Weibel | Arzneimitteldosenform und -herstellungsverfahren |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
MXPA05012317A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas. |
TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
MXPA06013163A (es) * | 2004-05-11 | 2007-02-13 | Pfizer Prod Inc | Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b. |
GB0416861D0 (en) * | 2004-07-29 | 2004-09-01 | Quadrant Drug Delivery Ltd | Composition |
KR20070084123A (ko) * | 2004-10-15 | 2007-08-24 | 엔.브이.오가논 | 양극성 장애 및 관련 증상의 치료 |
RS51341B (en) | 2005-04-07 | 2011-02-28 | N.V. Organon | INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole |
US7872147B2 (en) | 2005-04-07 | 2011-01-18 | N. V. Organon | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
SI1710245T1 (sl) * | 2005-04-07 | 2007-12-31 | Organon Nv | Kristalna oblika asenapin maleata |
US7741358B2 (en) | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
US7750167B2 (en) | 2006-07-05 | 2010-07-06 | N.V. Organon | Process for the preparation of asenapine and intermediate products used in said process |
US7875729B2 (en) | 2007-01-05 | 2011-01-25 | Synthon Bv | Process for making asenapine |
UY31531A1 (es) * | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
CA2727573A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
WO2010127674A1 (en) * | 2009-05-06 | 2010-11-11 | Sunin K/S | Transdermal compositions of asenapine for the treatment of psychiatric disorders |
JP5801295B2 (ja) | 2009-06-24 | 2015-10-28 | メルク・シャープ・エンド・ドーム・ベー・フェー | アセナピンを含有する注射可能な配合物およびそれを用いた処置方法 |
TW201118102A (en) | 2009-07-29 | 2011-06-01 | Organon Nv | Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same |
CA2802990A1 (en) | 2010-06-18 | 2011-12-22 | Dr. Reddy's Laboratories Ltd. | Asenapine maleate |
WO2012013766A1 (en) | 2010-07-29 | 2012-02-02 | Laboratorios Lesvi, S.L. | Novel process for the preparation of asenapine |
WO2012038975A2 (en) * | 2010-09-22 | 2012-03-29 | Msn Laboratories Limited | Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof |
CA2818025A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
WO2012066565A2 (en) | 2010-11-16 | 2012-05-24 | Cadila Healthcare Limited | Asenapine maleate amorphous and crystalline form and process for preparation thereof |
EP2468750A1 (en) | 2010-12-13 | 2012-06-27 | Chemo Ibérica, S.A. | Polymorphic forms of asenapine maleate and processes for their preparation |
WO2012123325A1 (en) | 2011-03-11 | 2012-09-20 | Medichem S.A. | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID |
EP2524919A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids |
US9505771B2 (en) * | 2011-05-18 | 2016-11-29 | Laboratories Lesvi S.L. | Stable micronised monoclin form of asenapine maleate and its synthesis |
US9533994B2 (en) | 2011-05-18 | 2017-01-03 | Laboratorios Lesvi S.L. | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution |
WO2013041604A1 (en) | 2011-09-21 | 2013-03-28 | Sandoz Ag | Crystal form of asenapine maleate |
EP2572703A1 (en) | 2011-09-21 | 2013-03-27 | Hexal AG | Compressed oral dosage form for asenapine maleate |
CN102657635B (zh) * | 2012-05-04 | 2013-08-07 | 上海现代药物制剂工程研究中心有限公司 | 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法 |
ITMI20121810A1 (it) | 2012-10-24 | 2014-04-25 | Chemo Iberica Sa | Poliformi di maleato di asenapina e processo per la loro preparazione |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
US9597291B2 (en) | 2012-12-11 | 2017-03-21 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
WO2014100418A2 (en) | 2012-12-20 | 2014-06-26 | Kashiv Pharma, Llc | Orally disintegrating tablet formulation for enhanced bioavailability |
CN103893139B (zh) * | 2012-12-28 | 2018-06-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种阿塞那平组合物及其制备方法 |
CN103120688A (zh) * | 2013-01-11 | 2013-05-29 | 盛世泰科生物医药技术(苏州)有限公司 | 一种闪释制剂的药物组合 |
US9545376B2 (en) | 2013-01-23 | 2017-01-17 | Arx, Llc | Production of unit dose constructs |
WO2014127786A1 (en) | 2013-02-22 | 2014-08-28 | Zentiva, K.S. | Orally disintegrating pharmaceutical composition comprising asenapine |
WO2014207664A2 (en) * | 2013-06-28 | 2014-12-31 | Alembic Pharmaceuticals Limited | Stable pharmaceutical composition of asenapine |
EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
US20170007537A1 (en) * | 2014-02-18 | 2017-01-12 | Hetero Research Foundation | Pharmaceutical compositions of asenapine |
PT3125893T (pt) | 2014-04-04 | 2023-11-21 | Intra Cellular Therapies Inc | Gama-carbolinas fusionadas com heterociclo deuterado como antagonistas de recetores 5-ht2a |
TR201509009A1 (en) * | 2014-12-11 | 2017-02-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | THIN FILM STRIP OF ASENAPINE |
EP3307245A1 (en) | 2015-06-11 | 2018-04-18 | Alrise Biosystems GmbH | Process for the preparation of drug loaded microparticles |
WO2016205739A1 (en) | 2015-06-19 | 2016-12-22 | Belew Mekonnen | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
KR20180099905A (ko) | 2016-01-26 | 2018-09-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
IL297676B2 (en) | 2016-03-25 | 2023-12-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
US10085971B2 (en) | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
CN110087640A (zh) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
MX2020009668A (es) | 2018-03-16 | 2021-01-08 | Intra Cellular Therapies Inc | Métodos novedosos. |
CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法 |
KR20210022656A (ko) | 2018-06-20 | 2021-03-03 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피 치료 시스템 |
BR112021003838A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
CA3141223A1 (en) | 2019-07-07 | 2021-01-14 | Sharon Mates | Novel methods |
WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
IE45770B1 (en) * | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
FR2480283A1 (fr) * | 1980-04-10 | 1981-10-16 | Science Union & Cie | Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament |
JPS5967218A (ja) * | 1982-10-07 | 1984-04-16 | Grelan Pharmaceut Co Ltd | 軟質な口腔製剤 |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA2027243A1 (en) * | 1989-10-17 | 1991-04-18 | Everett H. Ellinwood, Jr. | Intraoral formulated trifluorobenzodiazepines and the use thereof |
WO1992017209A1 (en) * | 1991-04-08 | 1992-10-15 | Sumitomo Pharmaceuticals Company, Limited | Porous solid preparation containing physiologically active protein substance |
CA2095499A1 (en) * | 1992-05-08 | 1993-11-09 | Petrus J. M. Van Den Oetelaar | Depot preparation |
EP0569096A1 (en) * | 1992-05-08 | 1993-11-10 | Akzo Nobel N.V. | Depot preparation |
-
1995
- 1995-03-01 DE DE201012000050 patent/DE122010000050I2/de active Active
- 1995-03-01 US US08/693,064 patent/US5763476A/en not_active Expired - Lifetime
- 1995-03-01 NZ NZ282394A patent/NZ282394A/en not_active IP Right Cessation
- 1995-03-01 RU RU96120090/14A patent/RU2139051C1/ru active Protection Beyond IP Right Term
- 1995-03-01 EP EP95912188A patent/EP0746317B1/en not_active Expired - Lifetime
- 1995-03-01 BR BR9506924A patent/BR9506924A/pt not_active Application Discontinuation
- 1995-03-01 DK DK95912188T patent/DK0746317T3/da active
- 1995-03-01 CZ CZ962541A patent/CZ284633B6/cs not_active IP Right Cessation
- 1995-03-01 KR KR1019960704774A patent/KR100330942B1/ko not_active IP Right Cessation
- 1995-03-01 HU HU9602383A patent/HU225051B1/hu active Protection Beyond IP Right Term
- 1995-03-01 JP JP52270395A patent/JP4099224B2/ja not_active Expired - Lifetime
- 1995-03-01 PL PL95316080A patent/PL180465B1/pl unknown
- 1995-03-01 CN CN95191906A patent/CN1079670C/zh not_active Expired - Lifetime
- 1995-03-01 CA CA002182981A patent/CA2182981C/en not_active Expired - Lifetime
- 1995-03-01 ES ES95912188T patent/ES2118584T3/es not_active Expired - Lifetime
- 1995-03-01 AU AU19478/95A patent/AU692530B2/en not_active Expired
- 1995-03-01 AT AT95912188T patent/ATE167057T1/de active
- 1995-03-01 DE DE69502939T patent/DE69502939T2/de not_active Expired - Lifetime
- 1995-03-01 WO PCT/EP1995/000765 patent/WO1995023600A1/en active IP Right Grant
-
1996
- 1996-08-30 NO NO19963639A patent/NO308772B1/no not_active IP Right Cessation
- 1996-08-30 FI FI963398A patent/FI117923B/fi not_active IP Right Cessation
-
1997
- 1997-05-13 BR BR1100625-0A patent/BR1100625A/pt active IP Right Grant
-
1998
- 1998-07-14 HK HK98109126A patent/HK1008417A1/xx not_active IP Right Cessation
-
2006
- 2006-08-10 JP JP2006217762A patent/JP4616810B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-04 LU LU91751C patent/LU91751I2/fr unknown
- 2010-12-13 NO NO2010024C patent/NO2010024I2/no unknown
- 2010-12-23 FR FR10C0056C patent/FR10C0056I2/fr active Active